Peregrine Pharmaceuticals (NASDAQ:PPHM)

CAPS Rating: 2 out of 5

A biopharmaceutical company with a portfolio of clinical stage and pre-clinical product candidates using monoclonal antibodies for the treatment of cancer and viral diseases.

Recs

0
Player Avatar pchop123 (79.73) Submitted: 12/4/2012 10:21:23 AM : Underperform Start Price: $1.33 PPHM Score: +7.82

Where are the positives???

Featured Broker Partners


Advertisement